Last reviewed · How we verify
Abdominal wall block with liposomal bupivicaine — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Abdominal wall block with liposomal bupivicaine (Abdominal wall block with liposomal bupivicaine) — University of California, Los Angeles.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Abdominal wall block with liposomal bupivicaine TARGET | Abdominal wall block with liposomal bupivicaine | University of California, Los Angeles | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Abdominal wall block with liposomal bupivicaine CI watch — RSS
- Abdominal wall block with liposomal bupivicaine CI watch — Atom
- Abdominal wall block with liposomal bupivicaine CI watch — JSON
- Abdominal wall block with liposomal bupivicaine alone — RSS
Cite this brief
Drug Landscape (2026). Abdominal wall block with liposomal bupivicaine — Competitive Intelligence Brief. https://druglandscape.com/ci/abdominal-wall-block-with-liposomal-bupivicaine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab